MRAI Marpai (MRAI) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0001844392
Activist 13DC-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about MRAI
Insiders, 180 days
+$3.4K net bought
2 buyers
Activist stakes (13D), 180 days
1 filing
Largest: 9.3% of the class
Marpai insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Marpai, Inc. insiders bought a net $3.4K of stock across 69 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 5, 2024.
- -39.7% median (-47.4% mean) 90-day return after 3 previous buys.
- The trade is 0.1% of the 1,024,192 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Chief Financial Officer Johnson Steve Andrew bought about $682 of MRAI on Jun 2, 2026; 1 other insider bought within 30 days.Context
- 17 earlier Form 4 trades (code P or S) here by this insider (17 buys), the last on Nov 7, 2025.
- -40.8% median (-18.9% mean) 90-day return after 16 previous buys.
- The trade is 0.9% of the 1,099,073 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Director EITAN YARON bought about $2.7K of MRAI on May 20, 2026; 1 other insider bought within 30 days.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Dec 5, 2024.
- -39.7% median (-15.9% mean) 90-day return after 15 previous buys.
- The trade is 9.2% of the 1,089,073 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director EITAN YARON bought about $100.0K of MRAI on Nov 7, 2025; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 18.4% of the 272,000 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director SHIV SAGIV bought about $50.0K of MRAI on Nov 7, 2025; 2 other insiders bought within 30 days.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 28, 2024.
- -8.0% median (+9.5% mean) 90-day return after 4 previous buys.
- The trade is 13.9% of the 359,200 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director PONS ROBERT M bought about $50.0K of MRAI on Nov 7, 2025; 2 other insiders bought within 30 days.69 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$3.4K over 180 days
more than 73% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-35.8% year over year
below 95% of Healthcare Services
Margin
-91.5% net margin
below 91% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
0.3% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 79% of Healthcare Services
The situation: each line is one rule over one dataset
Calvin Steven Mitchell disclosed a 5%+ stake (9.3%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MRAI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+105.7%12M
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MRAI: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in MRAI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Calvin Steven Mitchell
Activist 13D · 2026-08-13
9.3%
Benchmark Assets, LLC
Activist 13D · 2026-08-13
9.3%
MRAI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.2M
$1.2M
$1.3M
-81%
n/a
2024
$362.0K
$712.0K
$514.0K
-75%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $3.4K bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
MRAI financials
Revenue growth
-35.8%
XBRL, annual
Net margin
-91.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$16.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM MRAI
| FY Dec 2025 | $18.1M |
| FY Dec 2024 | $28.2M |
| FY Dec 2023 | $37.2M |
| FY Dec 2022 | $24.3M |
| FY Dec 2021 | n/a |
| Jun 2026 | $4.2M |
| Mar 2026 | $4.4M |
| Dec 2025 | $4.0M |
| Sep 2025 | $4.0M |
| Jun 2025 | $4.7M |
| Mar 2025 | $5.4M |
| Dec 2024 | $6.6M |
| Sep 2024 | $7.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-83.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM MRAI
| FY Dec 2025 | -74.9% |
| FY Dec 2024 | -78.4% |
| FY Dec 2023 | -77.4% |
| FY Dec 2022 | -108.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | -110.0% |
| Mar 2026 | -71.6% |
| Dec 2025 | -65.7% |
| Sep 2025 | -86.5% |
| Jun 2025 | -93.9% |
| Mar 2025 | -56.6% |
| Dec 2024 | -17.5% |
| Sep 2024 | -50.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$9.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM MRAI
| FY Dec 2025 | -$7.8M |
| FY Dec 2024 | -$15.5M |
| FY Dec 2023 | -$16.1M |
| FY Dec 2022 | -$35.6M |
| FY Dec 2021 | -$11.1M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 3.78x |
| FY Dec 2021 | 0.10x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.42x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt MRAI
| FY Dec 2025 | -0.38x |
| FY Dec 2024 | -0.63x |
| FY Dec 2023 | -0.79x |
| FY Dec 2022 | -1.52x |
| FY Dec 2021 | -3.60x |
| Jun 2026 | -0.42x |
| Mar 2026 | -0.39x |
| Dec 2025 | -0.38x |
| Sep 2025 | -0.39x |
| Jun 2025 | -0.64x |
| Mar 2025 | -0.65x |
| Dec 2024 | -0.63x |
| Sep 2024 | -0.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -147.7% |
| FY Dec 2021 | -122.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-135.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets MRAI
| FY Dec 2025 | -114.0% |
| FY Dec 2024 | -99.1% |
| FY Dec 2023 | -70.4% |
| FY Dec 2022 | -56.2% |
| FY Dec 2021 | -63.0% |
| Jun 2026 | -135.2% |
| Mar 2026 | -111.0% |
| Dec 2025 | -114.0% |
| Sep 2025 | -74.7% |
| Jun 2025 | -73.1% |
| Mar 2025 | -95.0% |
| Dec 2024 | -99.1% |
| Sep 2024 | -94.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | -933.3% |
| FY Dec 2023 | -128.8% |
| FY Dec 2022 | -82.1% |
| FY Dec 2021 | -85.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | -1,042% |
| Dec 2024 | -933.3% |
| Sep 2024 | -296.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$101.9M
market value at close 2026-10-27 on 2026-08-13 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value MRAI
| FY Dec 2025 | $34.1M |
| FY Dec 2024 | $36.2M |
| FY Dec 2023 | $32.5M |
| FY Dec 2022 | $69.7M |
| FY Dec 2021 | $336.4M |
| Jun 2026 | $40.7M |
| Mar 2026 | $27.0M |
| Dec 2025 | $34.1M |
| Sep 2025 | $42.0M |
| Jun 2025 | $38.0M |
| Mar 2025 | $32.5M |
| Dec 2024 | $36.2M |
| Sep 2024 | $31.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-11.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield MRAI
| FY Dec 2025 | -52.6% |
| FY Dec 2024 | -118.8% |
| FY Dec 2023 | -117.9% |
| FY Dec 2022 | -59.0% |
| FY Dec 2021 | -3.1% |
| Jun 2026 | -45.1% |
| Mar 2026 | -111.5% |
| Dec 2025 | -52.6% |
| Sep 2025 | -32.9% |
| Jun 2025 | -60.4% |
| Mar 2025 | -79.3% |
| Dec 2024 | -118.8% |
| Sep 2024 | -183.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing MRAI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $18.1M | $28.2M | $37.2M | $24.3M |
| Operating income | -$13.6M | -$22.1M | -$28.0M | -$27.0M |
| Net income | -$13.6M | -$22.1M | -$28.8M | -$26.5M |
| EPS (diluted) | -0.95 | -1.92 | -4.14 | -5.23 |
| Operating cash flow | -$7.5M | -$15.2M | -$15.7M | -$35.2M |
| Cash | $133.0K | $764.0K | $1.1M | $13.8M |
| Long-term debt | $11.4M | $17.8M | $19.4M | $20.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
MRAI Stock Sonar score 4/7 axes
Find similar shapesCompareMRAI ranks highest on risk and compliance (86th percentile) and insider conviction (79th), and lowest on growth (12th), among Healthcare Services peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MRAI filings, in plain words
Are Marpai insiders buying or selling MRAI?
In the 180 days to 2026-10-28, Marpai insiders were net buyers, a net $3.4K across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-28, Marpai insiders were net buyers of MRAI, a net $3.4K across purchases and sales reported on Form 4 by 2 buyers. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 9.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
